知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.019 秒)

    METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST VIRUS
    3.
    发明申请
    METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST VIRUS 审中-公开
    用于免疫病毒的方法和组合物

    公开(公告)号：US20150335728A1

    公开(公告)日：2015-11-26

    申请号：US14182296

    申请日：2014-02-18

    申请人： Academia Sinica

    发明人： Chi-Huey WONG ,  Che MA ,  Cheng-Chi WANG ,  Juine-Ruey CHEN

    IPC分类号： A61K39/145 ,  C12N7/00

    CPC分类号： A61K39/145 ,  A61K39/12 ,  A61K2039/55505 ,  C07K16/1018 ,  C07K2317/76 ,  C12N7/00 ,  C12N2740/11034 ,  C12N2740/16034 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12N2760/16171 ,  C12N2770/24134 ,  Y02A50/386

    摘要： Immunogenic compositions comprising partially glycosylated viral glycoproteins for use as vaccines against viruses are provided. Vaccines formulated using mono-, di-, or tri-glycosylated viral surface glycoproteins and polypeptides provide potent and broad protection against viruses, even across strains. Pharmaceutical compositions comprising monoglycosylated hemagglutinin polypeptides and vaccines generated therefrom and methods of their use for prophylaxis or treatment of viral infections are disclosed. Methods and compositions are disclosed for influenza virus HA, NA and M2, RSV proteins F, G and SH, Dengue virus glycoproteins M or E, hepatitis C virus glycoprotein E1 or E2 and HIV glycoproteins gp120 and gp41.

    摘要翻译： 提供了包含部分糖基化的病毒糖蛋白的免疫原性组合物，其用作抗病毒疫苗。 使用单糖，二糖或三糖基化的病毒表面糖蛋白和多肽配制的疫苗甚至可以跨毒株提供有效和广泛的防病毒保护。 公开了包含单糖基化血凝素多肽和由其产生的疫苗的药物组合物及其用于预防或治疗病毒感染的方法。 公开了用于流感病毒HA，NA和M2，RSV蛋白F，G和SH，登革病毒糖蛋白M或E，丙型肝炎病毒糖蛋白E1或E2和HIV糖蛋白gp120和gp41的方法和组合物。

    IMPROVED CORONAVIRUS VACCINE
    8.
    发明公开
    IMPROVED CORONAVIRUS VACCINE 审中-公开

    公开(公告)号：US20240016917A1

    公开(公告)日：2024-01-18

    申请号：US18005573

    申请日：2022-04-12

    申请人： ACADEMIA SINICA

    发明人： Che MA ,  Chi-Huey WONG ,  Han-Yi HUANG

    IPC分类号： A61K39/215 ,  A61P31/04

    CPC分类号： A61K39/215 ,  A61P31/04 ,  A61K2039/55505

    摘要： The present disclosure provides a glycoengineered SARS-CoV-2 spike protein which is capable of eliciting an enhanced immune response relative to a native spike protein of SARS-CoV-2 and its variants. The glycoengineered spike protein exposes the glycosylation sites and at the same time preserves the tertiary structure of the spike protein. The present disclosure therefore provides improved immunogens, vaccines, and methods for better prevention and treatment of the emerging coronavirus infections.

    ANTIVIRAL LECTIN AND USES THEREOF
    10.
    发明申请
    ANTIVIRAL LECTIN AND USES THEREOF 有权

    公开(公告)号：US20210386820A1

    公开(公告)日：2021-12-16

    申请号：US17274122

    申请日：2019-09-06

    申请人： ACADEMIA SINICA

    发明人： Che MA ,  Yu-Min LIU ,  Jia-Tsrong JAN

    IPC分类号： A61K38/17 ,  A61P31/16

    摘要： The present invention relates to antiviral lectin and uses thereof. Particularly, the present invention relates to a complex-type (CX-type) and/or hybrid-type (HY-type) glycan binding lectin for use in treating or preventing influenza virus infection. The present invention also provides a method for treating or preventing influenza virus infection by administrating to a subject in need said lectin or a composition comprising the same.